Standout Papers

The NAFLD fibrosis score 1990 2026 2002 2014 2.3k
  1. The NAFLD fibrosis score (2007)
    Paul Angulo, Jason M. Hui et al. Hepatology
  2. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease (2010)
    Giovanni Targher, Christopher P. Day et al. New England Journal of Medicine
  3. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (2013)
    Quentin M. Anstee, Giovanni Targher et al. Nature Reviews Gastroenterology & Hepatology
  4. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications (1999)
    Guruprasad P. Aithal, Christopher P. Day et al. The Lancet
  5. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. (1990)
    Christopher P. Day, Janet M. McComb et al. Heart
  6. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis (2017)
    Anna Mae Diehl, Christopher P. Day New England Journal of Medicine
  7. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management (2014)
    Stuart McPherson, Timothy Hardy et al. Journal of Hepatology
  8. Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients (2007)
    Giovanni Targher, Lorenzo Bertolini et al. Diabetes Care
  9. The natural history of nonalcoholic fatty liver: A follow-up study (1995)
    Oliver James, Alastair D. Burt et al. Hepatology
  10. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin (2009)
    Ann K. Daly, Peter T. Donaldson et al. Nature Genetics
  11. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (2010)
    Stuart McPherson, Sheila F. Stewart et al. Gut
  12. Nonalcoholic fatty liver disease (2015)
    Elizabeth M. Brunt, Vincent Wai‐Sun Wong et al. Nature Reviews Disease Primers
  13. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers (2007)
    Indra Neil Guha, Julie Parkes et al. Hepatology
  14. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016)
    Stuart McPherson, Timothy Hardy et al. The American Journal of Gastroenterology
  15. Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease† (2010)
    Luca Valenti, Ahmad Al‐Serri et al. Hepatology
  16. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum (2016)
    Timothy Hardy, Fiona Oakley et al. Annual Review of Pathology Mechanisms of Disease
  17. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014)
    Yang‐Lin Liu, Helen L. Reeves et al. Nature Communications
  18. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review (2011)
    Christian Thoma, Christopher P. Day et al. Journal of Hepatology
  19. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma (2014)
    Liu Yl, Gillian Patman et al. Journal of Hepatology
  20. Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (2013)
    Paul Angulo, Elisabetta Bugianesi et al. Gastroenterology

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 238 standout
Sub-graph 1 of 17

Citing Papers

Acquisition of epithelial plasticity in human chronic liver disease
2024 StandoutNature
An ER‐targeted, Viscosity‐sensitive Hemicyanine Dye for the Diagnosis of Nonalcoholic Fatty Liver and Photodynamic Cancer Therapy by Activating Pyroptosis Pathway
2024 Standout
15 intermediate papers

Works of Christopher P. Day being referenced

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
2017 Standout
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
2016 Standout
and 20 more

Author Peers

Author Last Decade Papers Cites
Christopher P. Day 22363 9924 9677 183 30.3k
Geoffrey C. Farrell 19440 9801 6780 213 25.5k
Brent A. Neuschwander‐Tetri 24212 9883 10995 186 29.7k
Naga Chalasani 25932 13934 9759 485 35.8k
Arthur J. McCullough 27432 11779 11652 292 34.4k
Elisabetta Bugianesi 26731 10190 12431 282 31.7k
Joel E. Lavine 23582 9615 11524 144 27.6k
Paul Angulo 21596 11575 9010 155 25.9k
Elizabeth M. Brunt 38092 17176 15206 268 48.9k
Ariel E. Feldstein 16818 6164 6567 218 26.3k
Quentin M. Anstee 18861 8645 7626 247 22.8k

All Works

Loading papers...

Rankless by CCL
2026